Guild restates concern over out of pocket costs

This is a preview of subscriber content

Subscribe now to continue reading.

"We have raised concerns both with the Department of Health and Minister Hunt's office of the potential for increased out of pocket costs for patients receiving a medicine under that general co-payment that do not have a concession or entitlement card," said the president of the Guild's Victorian branch Anthony Tassone. …

Subscribe now to continue reading.

Guild restates concern over out of pocket costs

This is a preview of subscriber content

Latest Video

Most Read

AusBiotech appoints experienced Sanofi leader as its new chief executive

'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'

Don't be alarmed by a flat or declining forecast, because it will rise over time

Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?

Rare Cancers Australia welcomes new appointments to its board of directors

New Stories

Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate

Novartis nominates ex-BMS chief executive as its new chair

'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'

AusBiotech appoints experienced Sanofi leader as its new chief executive

Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?

Rare Cancers Australia welcomes new appointments to its board of directors

BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics

Sign In

Guild restates concern over out of pocket costs

This is a preview of subscriber content

Latest Video

Most Read

AusBiotech appoints experienced Sanofi leader as its new chief executive

'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'

Don't be alarmed by a flat or declining forecast, because it will rise over time

Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?

Rare Cancers Australia welcomes new appointments to its board of directors

Follow Us

New Stories

Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate

Novartis nominates ex-BMS chief executive as its new chair

'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'

AusBiotech appoints experienced Sanofi leader as its new chief executive

Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?

Rare Cancers Australia welcomes new appointments to its board of directors

BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics